<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00679432</url>
  </required_header>
  <id_info>
    <org_study_id>CB-01-02/01</org_study_id>
    <nct_id>NCT00679432</nct_id>
  </id_info>
  <brief_title>(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis</brief_title>
  <official_title>Efficacy and Safety of New Oral Budesonide-MMX™ (CB-01-02) 6 mg and 9 mg Extended Release Tablet Formulations in Patients With Mild or Moderate, Active Ulcerative Colitis. A Multicenter, Randomized, Double-blind, Double Dummy Comparative Study Versus Placebo, With an Additional Reference Arm Evaluating Asacol® 2400 mg.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valeant Pharmaceuticals International, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valeant Pharmaceuticals International, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare Budesonide MMX™ 6 mg and Budesonide MMX™ 9 mg tablets
      to placebo and to Asacol 6x 400 mg tablets over an 8-week treatment period to determine if
      Budesonide MMX™ is effective in the treatment of ulcerative colitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each patient will receive one of the following regimens in the morning after breakfast:

        1. one budesonide-MMX™ 6 mg tablet plus two placebo Asacol® over encapsulated tablets, or

        2. one budesonide-MMX™ 9 mg tablet plus two placebo Asacol® over encapsulated tablets, or

        3. two placebo Asacol® over encapsulated tablets plus one placebo budesonide tablet, or

        4. two Asacol® 400 mg over encapsulated tablets plus one placebo budesonide tablet, daily
           for 8 weeks.

      Each patient will also receive on each day after the midday meal and after the evening meal
      either:

        -  two Asacol® 400 mg over-encapsulated tablets (Group 4), or

        -  the equivalent placebo Asacol® over-encapsulated tablets, (Groups 1, 2 and 3)

      Hence, each patient is to take seven tablets per day of active or placebo study medication as
      per the randomization schedule. Placebo tablets of budesonide-MMX™ and placebo
      over-encapsulated tablets of Asacol® will be used to maintain the study blind using a
      double-dummy technique.

      During the study, five visits to the clinical center are scheduled: one at Screening and
      three in the double-blind treatment period (Day 1, Day 14, Day 28 and Day 56). A safety
      follow up visit will take place about 2 weeks after the final study visit. If a patient is
      withdrawn from the study before Day 56, they will be asked to attend the study center as soon
      as possible thereafter so that the Final visit assessments can be conducted.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical and Endoscopic Remission.</measure>
    <time_frame>8 weeks</time_frame>
    <description>Clinical and endoscopic remission defined as a Ulcerative Colitis Disease Activity Index (UCDAI) score ≤ 1, with subscores of 0 for rectal bleeding, stool frequency, and mucosal appearance and with a ≥ 1 point reduction in the endoscopic index score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Improvement.</measure>
    <time_frame>8 weeks</time_frame>
    <description>Clinical improvement, defined as a ≥ 3-point improvement in UCDAI from baseline to the end of Week 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic Improvement</measure>
    <time_frame>8 weeks</time_frame>
    <description>Greater or equal to a 1 point improvement in the mucosal appearance subscore of the UCDAI, from baseline to week 8.
As per the hierarchical testing procedure for secondary endpoints, because clinical improvement was not statistically significant in the ITT population, formal statistical comparisons for endoscopic improvement between the 2 budesonide MMX groups and placebo were not conducted.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">510</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>1: budesonide-MMX® 6 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One budesonide-MMX® 6 mg plus two placebo Asacol® overencapsulated tablets daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2: budesonide-MMX® 9 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One budesonide-MMX® 9 mg plus two placebo Asacol® overencapsulated tablets daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two placebo Asacol® overencapsulated tablets plus one placebo Budesonide MMX® tablet daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4: Asacol® 400 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two Asacol® 400 mg overencapsulated tablets plus one placebo budesonide MMX® tablet daily in the morning after breakfast and two Asacol® 400 mg overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sampling, endoscopy</intervention_name>
    <description>Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores</description>
    <arm_group_label>1: budesonide-MMX® 6 mg</arm_group_label>
    <arm_group_label>2: budesonide-MMX® 9 mg</arm_group_label>
    <arm_group_label>3: Placebo</arm_group_label>
    <arm_group_label>4: Asacol® 400 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>budesonide-MMX® 6 mg</intervention_name>
    <description>6 mg/day, 6 mg tablets</description>
    <arm_group_label>1: budesonide-MMX® 6 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>budesonide-MMX® 9 mg</intervention_name>
    <description>9 mg/day, 9 mg tablets</description>
    <arm_group_label>2: budesonide-MMX® 9 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>3: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asacol® 400 mg</intervention_name>
    <description>2400 mg/day, 400 mg tablets</description>
    <arm_group_label>4: Asacol® 400 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients fulfilling the following criteria at the screening visit are eligible for
             participation in the study:

               -  Male and female patients, 18-75 years old, suffering from ulcerative colitis for
                  at least 6 months.

               -  Diagnosis of ulcerative colitis in active phase, of mild or moderate entity with
                  Ulcerative Colitis Disease Activity Index (UCDAI) ≥ 4 and ≤ 10 according to
                  Sutherland.

               -  All females of child-bearing potential must have a negative serum pregnancy test
                  immediately prior to enrollment. In addition, all females of child-bearing
                  potential must agree to be completely abstinent or be using an accepted form of
                  contraception throughout the entire study period. Accepted forms of contraception
                  are defined as those with a failure rate &lt;1% when properly applied and include:
                  combination oral pill, some intra-uterine devices, and a sterilised partner in a
                  stable relationship. Female subjects must also not be actively breast-feeding
                  through the entire study period.

               -  Ability to comprehend the full nature and purpose of the study, including
                  possible risks and side effects.

               -  Ability to co-operate with the investigator and to comply with the requirements
                  of the entire study.

               -  Must be able to understand and voluntarily sign written informed consent prior to
                  inclusion in the study.

        Exclusion Criteria:

          -  Patients who meet any of the following criteria at screening visit are to be excluded
             from study participation:

               -  Patients with limited distal proctitis (from anal verge up to 15 cm above the
                  pectineal line).

               -  Patients with severe ulcerative colitis (UCDAI &gt;10).

               -  Patients with infectious colitis.

               -  Evidence or history of toxic megacolon.

               -  Severe anemia, leucopenia or granulocytopenia.

               -  Use of oral or rectal steroids in the last 4 weeks.

               -  Use of immuno-suppressive agents in the last 8 weeks before the study.

               -  Use of anti tumor necrosis factor alpha (anti-TNFα) agents in the last 3 months.

               -  Concomitant use of any rectal preparation.

               -  Concomitant use of antibiotics.

               -  Concurrent use of cytochrome P450 3A4 (CYP3A4) inducers or CYP3A4 inhibitors.

               -  Patients with intolerance to salicylates.

               -  Patients with verified, presumed or expected pregnancy or ongoing lactation.

               -  Patients with liver cirrhosis, or evident hepatic or renal disease or
                  insufficiency, and/or severe impairment of the bio-humoral parameters (i.e. 2 x
                  upper limit of normal for alanine aminotransferase [ALT], aspartate
                  aminotransferase [AST], gamma glutamyl transpeptidase [GGT] or creatinine).

               -  Patient with severe diseases in other organs and systems.

               -  Patients with local or systemic complications or other pathological states
                  requiring a therapy with corticosteroids and/or immuno-suppressive agents.

               -  Patients diagnosed with type 1 diabetes.

               -  Patients diagnosed with, or with a family history of, glaucoma.

               -  All patients with known hepatitis B, hepatitis C or with human immunodeficiency
                  virus (HIV), according to the local privacy policy.

               -  Participation in experimental therapeutic studies in the last 3 months. (Note:
                  patients who participated in observational only studies are not excluded).

               -  Any other medical condition that in the principal investigator's opinion would
                  make the administration of the study drug or study procedures hazardous to the
                  subject or obscure the interpretation of adverse events (AEs).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce Eric Sands</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5051</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5102</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5014</name>
      <address>
        <city>Sylacauga</city>
        <state>Alabama</state>
        <zip>35150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5088</name>
      <address>
        <city>Tuscon</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5044</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5099</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5075</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5087</name>
      <address>
        <city>Lakewood</city>
        <state>California</state>
        <zip>90712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5033</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5070</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5067</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5028</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5089</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5041</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5055</name>
      <address>
        <city>New Smyrna Beach</city>
        <state>Florida</state>
        <zip>32168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5074</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5032</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5009</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5110</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5047</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5003</name>
      <address>
        <city>Zephyrhills</city>
        <state>Florida</state>
        <zip>33542</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5016</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5056</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5103</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5085</name>
      <address>
        <city>Addison</city>
        <state>Illinois</state>
        <zip>60101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5068</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5086</name>
      <address>
        <city>Bloomington</city>
        <state>Indiana</state>
        <zip>47403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5053</name>
      <address>
        <city>Clive</city>
        <state>Iowa</state>
        <zip>50325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5008</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5090</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5025</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5092</name>
      <address>
        <city>Hollywood</city>
        <state>Maryland</state>
        <zip>20636</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5077</name>
      <address>
        <city>Prince Frederick</city>
        <state>Maryland</state>
        <zip>20678</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5046</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5115</name>
      <address>
        <city>Brockton</city>
        <state>Massachusetts</state>
        <zip>02301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5010</name>
      <address>
        <city>Chesterfield</city>
        <state>Michigan</state>
        <zip>48047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5006</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5004</name>
      <address>
        <city>Wyoming</city>
        <state>Michigan</state>
        <zip>49519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5105</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5094</name>
      <address>
        <city>Egg Harbor Township</city>
        <state>New Jersey</state>
        <zip>08234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5005</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>08053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5024</name>
      <address>
        <city>Vineland</city>
        <state>New Jersey</state>
        <zip>08360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5011</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5101</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5020</name>
      <address>
        <city>Pittsford</city>
        <state>New York</state>
        <zip>14534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5096</name>
      <address>
        <city>Fayetteville</city>
        <state>North Carolina</state>
        <zip>28304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5058</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5091</name>
      <address>
        <city>New Bern</city>
        <state>North Carolina</state>
        <zip>28562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5124</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5118</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5045</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5078</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45440</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5120</name>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <zip>44060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5066</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5065</name>
      <address>
        <city>Pottstown</city>
        <state>Pennsylvania</state>
        <zip>19464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5035</name>
      <address>
        <city>Sayre</city>
        <state>Pennsylvania</state>
        <zip>18840</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5107</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5130</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5095</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5021</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5076</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5108</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77079</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5019</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5036</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5063</name>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <zip>75061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5072</name>
      <address>
        <city>Kingwood</city>
        <state>Texas</state>
        <zip>77339</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5054</name>
      <address>
        <city>La Porte</city>
        <state>Texas</state>
        <zip>77571</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5030</name>
      <address>
        <city>Lewisville</city>
        <state>Texas</state>
        <zip>75057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5093</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5049</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5100</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5079</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5098</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5015</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5097</name>
      <address>
        <city>Christianburg</city>
        <state>Virginia</state>
        <zip>24073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 5119</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 6005</name>
      <address>
        <city>Abbotsford</city>
        <state>British Columbia</state>
        <zip>V2S 3N5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 6000</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1H2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 6014</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2K5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 6008</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 1J8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 6004</name>
      <address>
        <city>Richmond Hill</city>
        <state>Ontario</state>
        <zip>L4B 3P8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 6017</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3N5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 6001</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 6016</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 6002</name>
      <address>
        <city>Quebec</city>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 6006</name>
      <address>
        <city>Toronto</city>
        <zip>M3N 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 9001</name>
      <address>
        <city>Andhra Pradesh</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 9009</name>
      <address>
        <city>Andhra Pradesh</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 9012</name>
      <address>
        <city>Andhra Pradesh</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 9016</name>
      <address>
        <city>Andhra Pradesh</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 9006</name>
      <address>
        <city>Assam</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 9007</name>
      <address>
        <city>Gujarat</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 9004</name>
      <address>
        <city>Karnataka</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 9015</name>
      <address>
        <city>Karnataka</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 9003</name>
      <address>
        <city>Kerala</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 9002</name>
      <address>
        <city>Maharashtra</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 9008</name>
      <address>
        <city>Maharashtra</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 9010</name>
      <address>
        <city>Maharashtra</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 9011</name>
      <address>
        <city>Maharashtra</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 9013</name>
      <address>
        <city>Maharashtra</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 9017</name>
      <address>
        <city>Maharashtra</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 9018</name>
      <address>
        <city>Rajasthan</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 9005</name>
      <address>
        <city>Tamil Nadu</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 9014</name>
      <address>
        <city>Uttar Pradesh</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 7000</name>
      <address>
        <city>Colonia Centra</city>
        <state>La Paz Baja California Sur</state>
        <zip>23000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>India</country>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Sandborn WJ, Travis S, Moro L, Jones R, Gautille T, Bagin R, Huang M, Yeung P, Ballard ED 2nd. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology. 2012 Nov;143(5):1218-26.e1-2. doi: 10.1053/j.gastro.2012.08.003. Epub 2012 Aug 11.</citation>
    <PMID>22892337</PMID>
  </results_reference>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2008</study_first_submitted>
  <study_first_submitted_qc>May 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2008</study_first_posted>
  <results_first_submitted>April 25, 2014</results_first_submitted>
  <results_first_submitted_qc>July 3, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 1, 2014</results_first_posted>
  <disposition_first_submitted>December 1, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>February 9, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 13, 2012</disposition_first_posted>
  <last_update_submitted>July 3, 2014</last_update_submitted>
  <last_update_submitted_qc>July 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ulcerative colitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Mesalamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruited from August 2008 until May 2010.</recruitment_details>
      <pre_assignment_details>Diary data for symptoms will be collected prior to randomization. Lab testing and a colonoscopy will be done prior to randomization. 510 patients were randomized. One patient was not treated and was not included in baseline characteristics, efficacy, and safety analyses. 509 patients received study drug and were included in safety analyses.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1: Budesonide-MMX® 6 mg</title>
          <description>One budesonide-MMX® 6 mg plus two placebo Asacol® overencapsulated tablets daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
budesonide-MMX® 6 mg : 6 mg/day, 6 mg tablets
Blood sampling, endoscopy : Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores</description>
        </group>
        <group group_id="P2">
          <title>2: Budesonide-MMX® 9 mg</title>
          <description>One budesonide-MMX® 9 mg plus two placebo Asacol® overencapsulated tablets daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
Blood sampling, endoscopy : Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores
budesonide-MMX® 9 mg : 9 mg/day, 9 mg tablets</description>
        </group>
        <group group_id="P3">
          <title>3: Placebo</title>
          <description>Two placebo Asacol® overencapsulated tablets plus one placebo Budesonide MMX® tablet daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
Placebo : Placebo
Blood sampling, endoscopy : Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores</description>
        </group>
        <group group_id="P4">
          <title>4: Asacol® 400 mg</title>
          <description>Two Asacol® 400 mg overencapsulated tablets plus one placebo budesonide MMX® tablet daily in the morning after breakfast and two Asacol® 400 mg overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
Asacol® 400 mg : 2400 mg/day, 400 mg tablets
Blood sampling, endoscopy : Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="126"/>
                <participants group_id="P2" count="127"/>
                <participants group_id="P3" count="129"/>
                <participants group_id="P4" count="127"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="89"/>
                <participants group_id="P3" count="76"/>
                <participants group_id="P4" count="95"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="53"/>
                <participants group_id="P4" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Infectious colitis, normal histology</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomization error, return to prior Rx</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-Treat (ITT) population= primary population for efficacy/baseline characteristics analyses. ITT population= randomized patients who received study drug, and did not include patients with major entry criteria/GCP violations or normal histology at baseline (N= 509 randomized - 3[infectious colitis] - 17[normal histology at baseline] = 489).</population>
      <group_list>
        <group group_id="B1">
          <title>1: Budesonide-MMX® 6 mg</title>
          <description>One budesonide-MMX® 6 mg plus two placebo Asacol® overencapsulated tablets daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
budesonide-MMX® 6 mg : 6 mg/day, 6 mg tablets
Blood sampling, endoscopy : Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores</description>
        </group>
        <group group_id="B2">
          <title>2: Budesonide-MMX® 9 mg</title>
          <description>One budesonide-MMX® 9 mg plus two placebo Asacol® overencapsulated tablets daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
Blood sampling, endoscopy : Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores
budesonide-MMX® 9 mg : 9 mg/day, 9 mg tablets</description>
        </group>
        <group group_id="B3">
          <title>3: Placebo</title>
          <description>Two placebo Asacol® overencapsulated tablets plus one placebo Budesonide MMX® tablet daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
Placebo : Placebo
Blood sampling, endoscopy : Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores</description>
        </group>
        <group group_id="B4">
          <title>4: Asacol® 400 mg</title>
          <description>Two Asacol® 400 mg overencapsulated tablets plus one placebo budesonide MMX® tablet daily in the morning after breakfast and two Asacol® 400 mg overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
Asacol® 400 mg : 2400 mg/day, 400 mg tablets
Blood sampling, endoscopy : Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="121"/>
            <count group_id="B2" value="123"/>
            <count group_id="B3" value="121"/>
            <count group_id="B4" value="124"/>
            <count group_id="B5" value="489"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="122"/>
                    <measurement group_id="B3" value="115"/>
                    <measurement group_id="B4" value="118"/>
                    <measurement group_id="B5" value="472"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.2" spread="13"/>
                    <measurement group_id="B2" value="41.7" spread="12.2"/>
                    <measurement group_id="B3" value="41.7" spread="13.6"/>
                    <measurement group_id="B4" value="44" spread="12.4"/>
                    <measurement group_id="B5" value="42.7" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="55"/>
                    <measurement group_id="B5" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="68"/>
                    <measurement group_id="B4" value="69"/>
                    <measurement group_id="B5" value="273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="77"/>
                    <measurement group_id="B4" value="76"/>
                    <measurement group_id="B5" value="304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical and Endoscopic Remission.</title>
        <description>Clinical and endoscopic remission defined as a Ulcerative Colitis Disease Activity Index (UCDAI) score ≤ 1, with subscores of 0 for rectal bleeding, stool frequency, and mucosal appearance and with a ≥ 1 point reduction in the endoscopic index score.</description>
        <time_frame>8 weeks</time_frame>
        <population>Intent-to-Treat (ITT) population= primary population for efficacy/baseline characteristics analyses. ITT population= randomized patients who received study drug, and did not include patients with major entry criteria/GCP violations or normal histology at baseline (N= 509 randomized - 3[infectious colitis] - 17[normal histology at baseline] = 489).</population>
        <group_list>
          <group group_id="O1">
            <title>1: Budesonide-MMX® 6 mg</title>
            <description>One budesonide-MMX® 6 mg plus two placebo Asacol® overencapsulated tablets daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
budesonide-MMX® 6 mg : 6 mg/day, 6 mg tablets
Blood sampling, endoscopy : Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores</description>
          </group>
          <group group_id="O2">
            <title>2: Budesonide-MMX® 9 mg</title>
            <description>One budesonide-MMX® 9 mg plus two placebo Asacol® overencapsulated tablets daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
Blood sampling, endoscopy : Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores
budesonide-MMX® 9 mg : 9 mg/day, 9 mg tablets</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Two placebo Asacol® overencapsulated tablets plus one placebo Budesonide MMX® tablet daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
Placebo : Placebo
Blood sampling, endoscopy : Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores</description>
          </group>
          <group group_id="O4">
            <title>4: Asacol® 400 mg</title>
            <description>Two Asacol® 400 mg overencapsulated tablets plus one placebo budesonide MMX® tablet daily in the morning after breakfast and two Asacol® 400 mg overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
Asacol® 400 mg : 2400 mg/day, 400 mg tablets
Blood sampling, endoscopy : Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical and Endoscopic Remission.</title>
          <description>Clinical and endoscopic remission defined as a Ulcerative Colitis Disease Activity Index (UCDAI) score ≤ 1, with subscores of 0 for rectal bleeding, stool frequency, and mucosal appearance and with a ≥ 1 point reduction in the endoscopic index score.</description>
          <population>Intent-to-Treat (ITT) population= primary population for efficacy/baseline characteristics analyses. ITT population= randomized patients who received study drug, and did not include patients with major entry criteria/GCP violations or normal histology at baseline (N= 509 randomized - 3[infectious colitis] - 17[normal histology at baseline] = 489).</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="123"/>
                <count group_id="O3" value="121"/>
                <count group_id="O4" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2" lower_limit="7.2" upper_limit="19.3"/>
                    <measurement group_id="O2" value="17.9" lower_limit="11.1" upper_limit="24.7"/>
                    <measurement group_id="O3" value="7.4" lower_limit="2.8" upper_limit="12.1"/>
                    <measurement group_id="O4" value="12.1" lower_limit="6.4" upper_limit="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>All p-values were based on the Chi-square test; comparisons of budesonide MMX and placebo were conducted at the α = 0.025 level of significance and the comparison of Asacol and placebo were conducted at the α = 0.05 level of significance. The study was not powered to show statistical significance for Asacol versus budesonide MMX.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1393</p_value>
            <p_value_desc>P-Value was adjusted for multiple comparisons; two budesonide dosage strengths were compared with placebo.</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Difference in proportions</param_type>
            <param_value>5.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>13.4</ci_upper_limit>
            <estimate_desc>The difference in proportions was determined by subtracting the proportion of patients who reached the endpoint in the placebo group from that proportion in the active group (active minus placebo).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>See comments from the budesonide 6 mg versus placebo comparison (statistical analysis 1).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0143</p_value>
            <p_value_desc>See comments from the budesonide 6 mg versus placebo comparison (statistical analysis 1).</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Difference in proportions</param_type>
            <param_value>10.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.2</ci_lower_limit>
            <ci_upper_limit>18.7</ci_upper_limit>
            <estimate_desc>See comments from the budesonide 6 mg versus placebo comparison (statistical analysis 1).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>See comments from the budesonide 6 mg versus placebo comparison (statistical analysis 1).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2200</p_value>
            <p_value_desc>See comments from the budesonide 6 mg versus placebo comparison (statistical analysis 1).</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Difference in proportions</param_type>
            <param_value>4.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.7</ci_lower_limit>
            <ci_upper_limit>12.1</ci_upper_limit>
            <estimate_desc>See comments from the budesonide 6 mg versus placebo comparison (statistical analysis 1).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Improvement.</title>
        <description>Clinical improvement, defined as a ≥ 3-point improvement in UCDAI from baseline to the end of Week 8.</description>
        <time_frame>8 weeks</time_frame>
        <population>Intent-to-Treat (ITT) population= primary population for efficacy/baseline characteristics analyses. ITT population= randomized patients who received study drug, and did not include patients with major entry criteria/GCP violations or normal histology at baseline (N= 509 randomized - 3[infectious colitis] - 17[normal histology at baseline] = 489).</population>
        <group_list>
          <group group_id="O1">
            <title>1: Budesonide-MMX® 6 mg</title>
            <description>One budesonide-MMX® 6 mg plus two placebo Asacol® overencapsulated tablets daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
budesonide-MMX® 6 mg : 6 mg/day, 6 mg tablets
Blood sampling, endoscopy : Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores</description>
          </group>
          <group group_id="O2">
            <title>2: Budesonide-MMX® 9 mg</title>
            <description>One budesonide-MMX® 9 mg plus two placebo Asacol® overencapsulated tablets daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
Blood sampling, endoscopy : Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores
budesonide-MMX® 9 mg : 9 mg/day, 9 mg tablets</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Two placebo Asacol® overencapsulated tablets plus one placebo Budesonide MMX® tablet daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
Placebo : Placebo
Blood sampling, endoscopy : Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores</description>
          </group>
          <group group_id="O4">
            <title>4: Asacol® 400 mg</title>
            <description>Two Asacol® 400 mg overencapsulated tablets plus one placebo budesonide MMX® tablet daily in the morning after breakfast and two Asacol® 400 mg overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
Asacol® 400 mg : 2400 mg/day, 400 mg tablets
Blood sampling, endoscopy : Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Improvement.</title>
          <description>Clinical improvement, defined as a ≥ 3-point improvement in UCDAI from baseline to the end of Week 8.</description>
          <population>Intent-to-Treat (ITT) population= primary population for efficacy/baseline characteristics analyses. ITT population= randomized patients who received study drug, and did not include patients with major entry criteria/GCP violations or normal histology at baseline (N= 509 randomized - 3[infectious colitis] - 17[normal histology at baseline] = 489).</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="123"/>
                <count group_id="O3" value="121"/>
                <count group_id="O4" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.6" lower_limit="22.4" upper_limit="38.8"/>
                    <measurement group_id="O2" value="33.3" lower_limit="25.0" upper_limit="41.7"/>
                    <measurement group_id="O3" value="24.8" lower_limit="17.1" upper_limit="32.5"/>
                    <measurement group_id="O4" value="33.9" lower_limit="25.5" upper_limit="42.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Clinical improvement and endoscopic improvement were analyzed hierarchically. If at least one primary endpoint comparison was statistically significant, clinical improvement was to be compared between each budesonide MMX group and placebo at the α = 0.025 level of significance. If at least one comparison of clinical improvement was statistically significant, endoscopic improvement was to be compared between each budesonide MMX dose group and placebo at the α = 0.025 level of significance.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3146</p_value>
            <p_value_desc>P-Value was adjusted for multiple comparisons; two budesonide dosage strengths were compared with placebo.</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Difference in proportions</param_type>
            <param_value>5.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.5</ci_lower_limit>
            <ci_upper_limit>17.0</ci_upper_limit>
            <estimate_desc>The difference in proportions was determined by subtracting the proportion of patients who reached the endpoint in the placebo group from that proportion in the active group (active minus placebo).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>See comments from the budesonide 6 mg versus placebo comparison (statistical analysis 1).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1420</p_value>
            <p_value_desc>See comments from the budesonide 6 mg versus placebo comparison (statistical analysis 1).</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Difference in proportions</param_type>
            <param_value>8.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.8</ci_lower_limit>
            <ci_upper_limit>19.9</ci_upper_limit>
            <estimate_desc>See comments from the budesonide 6 mg versus placebo comparison (statistical analysis 1).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>See comments from the budesonide 6 mg versus placebo comparison (statistical analysis 1).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1189</p_value>
            <p_value_desc>See comments from the budesonide 6 mg versus placebo comparison (statistical analysis 1).</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Difference in proportions</param_type>
            <param_value>9.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>20.4</ci_upper_limit>
            <estimate_desc>See comments from the budesonide 6 mg versus placebo comparison (statistical analysis 1).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endoscopic Improvement</title>
        <description>Greater or equal to a 1 point improvement in the mucosal appearance subscore of the UCDAI, from baseline to week 8.
As per the hierarchical testing procedure for secondary endpoints, because clinical improvement was not statistically significant in the ITT population, formal statistical comparisons for endoscopic improvement between the 2 budesonide MMX groups and placebo were not conducted.</description>
        <time_frame>8 weeks</time_frame>
        <population>Intent-to-Treat (ITT) population= primary population for efficacy/baseline characteristics analyses. ITT population= randomized patients who received study drug, and did not include patients with major entry criteria/GCP violations or normal histology at baseline (N= 509 randomized - 3[infectious colitis] - 17[normal histology at baseline] = 489).</population>
        <group_list>
          <group group_id="O1">
            <title>1: Budesonide-MMX® 6 mg</title>
            <description>One budesonide-MMX® 6 mg plus two placebo Asacol® overencapsulated tablets daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
budesonide-MMX® 6 mg : 6 mg/day, 6 mg tablets
Blood sampling, endoscopy : Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores</description>
          </group>
          <group group_id="O2">
            <title>2: Budesonide-MMX® 9 mg</title>
            <description>One budesonide-MMX® 9 mg plus two placebo Asacol® overencapsulated tablets daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
Blood sampling, endoscopy : Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores
budesonide-MMX® 9 mg : 9 mg/day, 9 mg tablets</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Two placebo Asacol® overencapsulated tablets plus one placebo Budesonide MMX® tablet daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
Placebo : Placebo
Blood sampling, endoscopy : Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores</description>
          </group>
          <group group_id="O4">
            <title>4: Asacol® 400 mg</title>
            <description>Two Asacol® 400 mg overencapsulated tablets plus one placebo budesonide MMX® tablet daily in the morning after breakfast and two Asacol® 400 mg overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
Asacol® 400 mg : 2400 mg/day, 400 mg tablets
Blood sampling, endoscopy : Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores</description>
          </group>
        </group_list>
        <measure>
          <title>Endoscopic Improvement</title>
          <description>Greater or equal to a 1 point improvement in the mucosal appearance subscore of the UCDAI, from baseline to week 8.
As per the hierarchical testing procedure for secondary endpoints, because clinical improvement was not statistically significant in the ITT population, formal statistical comparisons for endoscopic improvement between the 2 budesonide MMX groups and placebo were not conducted.</description>
          <population>Intent-to-Treat (ITT) population= primary population for efficacy/baseline characteristics analyses. ITT population= randomized patients who received study drug, and did not include patients with major entry criteria/GCP violations or normal histology at baseline (N= 509 randomized - 3[infectious colitis] - 17[normal histology at baseline] = 489).</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="123"/>
                <count group_id="O3" value="121"/>
                <count group_id="O4" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.5" lower_limit="27" upper_limit="44.1"/>
                    <measurement group_id="O2" value="41.5" lower_limit="32.8" upper_limit="50.2"/>
                    <measurement group_id="O3" value="33.1" lower_limit="24.7" upper_limit="41.4"/>
                    <measurement group_id="O4" value="33.1" lower_limit="24.8" upper_limit="41.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>As per the hierarchical testing procedure for secondary endpoints, because clinical improvement was not statistically significant in the ITT population, formal statistical comparisons for endoscopic improvement between the 2 budesonide MMX groups and placebo were not conducted. The statistical comparison between the Asacol and placebo groups is shown here.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9991</p_value>
            <p_value_desc>P-Value was adjusted for multiple comparisons; two budesonide dosage strengths were compared with placebo.</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Difference in proportions</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.8</ci_lower_limit>
            <ci_upper_limit>11.8</ci_upper_limit>
            <estimate_desc>The difference in proportions was determined by subtracting the proportion of patients who reached the endpoint in the placebo group from that proportion in the active group (active minus placebo).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>56 day ± 2 day (study duration) + 30 day safety followup period.</time_frame>
      <desc>Adverse event data were analyzed using the safety population, defined as all patients who received study drug. 509 patients received study drug and were included in safety analyses.</desc>
      <group_list>
        <group group_id="E1">
          <title>1: Budesonide-MMX® 6 mg</title>
          <description>One budesonide-MMX® 6 mg plus two placebo Asacol® overencapsulated tablets daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
budesonide-MMX® 6 mg : 6 mg/day, 6 mg tablets
Blood sampling, endoscopy : Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores</description>
        </group>
        <group group_id="E2">
          <title>2: Budesonide-MMX® 9 mg</title>
          <description>One budesonide-MMX® 9 mg plus two placebo Asacol® overencapsulated tablets daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
Blood sampling, endoscopy : Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores
budesonide-MMX® 9 mg : 9 mg/day, 9 mg tablets</description>
        </group>
        <group group_id="E3">
          <title>3: Placebo</title>
          <description>Two placebo Asacol® overencapsulated tablets plus one placebo Budesonide MMX® tablet daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
Placebo : Placebo
Blood sampling, endoscopy : Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores</description>
        </group>
        <group group_id="E4">
          <title>4: Asacol® 400 mg</title>
          <description>Two Asacol® 400 mg overencapsulated tablets plus one placebo budesonide MMX® tablet daily in the morning after breakfast and two Asacol® 400 mg overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
Asacol® 400 mg : 2400 mg/day, 400 mg tablets
Blood sampling, endoscopy : Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA V11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pelvic abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pyoderma gangrenosum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA V11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="129"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="127"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="129"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="126"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Abdominal tenderness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="126"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="127"/>
                <counts group_id="E3" events="20" subjects_affected="20" subjects_at_risk="129"/>
                <counts group_id="E4" events="12" subjects_affected="12" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="126"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="129"/>
                <counts group_id="E4" events="9" subjects_affected="8" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="126"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="129"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="126"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="129"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="126"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="126"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Blood cortisol decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="129"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E3" events="8" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="29" subjects_affected="17" subjects_at_risk="126"/>
                <counts group_id="E2" events="14" subjects_affected="8" subjects_at_risk="127"/>
                <counts group_id="E3" events="31" subjects_affected="19" subjects_at_risk="129"/>
                <counts group_id="E4" events="15" subjects_affected="12" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="126"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="129"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Mood altered</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="129"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Huang, MD, Senior Medical Director, Clinical Research</name_or_title>
      <organization>Santarus, Inc.</organization>
      <phone>8583145700</phone>
      <email>mhuang@santarus.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

